FDA grants emergency use authorization for the third dose of enhanced vaccination of two mRNA new crown vaccines

Today, the U.

At present, the Delta (B.

According to Pfizer's public information, after the third dose of BNT162b2, the neutralizing antibody titer increased by more than 5 times in adults aged 18-55, and by more than 11 times in elderly people aged 65-80.

According to the data recently released by Moderna, the results of the phase 2 clinical trial testing the effect of the third dose of the enhanced vaccine showed that the level of neutralizing antibodies against the wild-type new coronavirus remained at 6 months after the second dose of vaccine.

For another example, AstraZeneca recently announced the effect of the third dose of the adenovirus new crown vaccine Vaxzevria (formerly known as AZD1222) in the preprint of The Lancet

It is worth mentioning that the human body's immune response to vaccines is a complex process, including not only the production of neutralizing antibodies, but also the T cell response against the virus

A few days ago, the FDA and CDC issued a statement stating that whether or not to receive the third dose of vaccine, and when to receive the third dose of vaccine, needs to be answered based on scientific analysis based on various data such as laboratory data and clinical trial data

We also expect that with the emergency use authorization of the third dose of enhanced vaccine, people will be better protected!

Reference materials:

[1] Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals.

[2]FDA Set to Greenlight Boosters for Some Vulnerable Patients.

[4]Moderna Business Updates First Quarter 2021 Financial Results.

[5]Flaxman et al.